Get started
Shukra Pharmaceuticals Ltd.Shukra Pharmaceuticals Ltd.Shukra Pharmaceuticals Ltd.

Shukra Pharmaceuticals Ltd.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsSeasonals

Documents


Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.
Earnings
2027
Earnings, Q1 FY2027
Aug 12, 2026
Strong revenue and profit growth in Q1 FY27, with robust performance in the pharmaceutical segment.
2026
Earnings, Q4 FY2026
May 7, 2026
Revenue and net profit surged year-over-year, with robust equity and no debt defaults.
Earnings, Q3 FY2026
Feb 4, 2026
Q3 FY26 revenue and profit surged, with strong audit review and MD re-appointment.
Earnings, Q2 FY2026
Nov 12, 2025
Q2 FY26 saw higher revenue, profit, and cash, with clean auditor review and no complaints.
Earnings, Q1 FY2026
Aug 12, 2025
Q1 FY26 saw strong revenue and profit growth with clean auditor review.
2025
Earnings, Q4 FY2025
Annual
May 29, 2025
Revenue and profit fell, but margins and liquidity improved; bonus issue and stock split completed.
Earnings, Q3 FY2025
Feb 14, 2025
Quarterly profit and revenue surged, with strengthened audit oversight.
Earnings, Q2 FY2025
Nov 13, 2024
Q2 FY2024-25 revenue grew, but net profit and EPS fell; cash reserves increased.
Earnings, Q1 FY2025
Aug 11, 2024
Q1 FY25 saw a significant drop in revenue and profit, but auditors raised no concerns.
2024
Earnings, Q4 FY2024
May 28, 2024
Earnings, Q3 FY2024
Feb 11, 2024
Earnings, Q2 FY2024
Nov 10, 2023